Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04094090 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia
A Phase 2 study of Keratoconus and Pellucid Marginal Corneal Degeneration, sponsored by Goodman Eye Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT04094090 is a Phase 2 study of Keratoconus and Pellucid Marginal Corneal Degeneration that is actively recruiting participants, run by Goodman Eye Center. The registered enrollment target is 500 participants, below the 1,157-participant average among 21 other Keratoconus trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04094090, a Phase 2 study of Keratoconus and Pellucid Marginal Corneal Degeneration, is actively recruiting participants, sponsored by Goodman Eye Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the safety and effectiveness of the PXL Platinum 330 system for performing corneal cross-linking (CXL) for the treatment of ectatic disorders.
Conditions Studied
Interventions
- COMBINATION_PRODUCT PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Study Locations (1)
California
- Goodman Eye Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2019-10-19 |
| Est. Completion | 2029-10-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04094090
The ClinicalTrials.gov registry entry for NCT04094090 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,157-participant average among 21 other Keratoconus trials with a reported enrollment target (57% lower). The listed sponsor is Goodman Eye Center, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Keratoconus appearing as the primary indexed condition, and to 1 intervention - of which PXL-330 Platinum device for crosslinking with Peschke riboflavin solution is the first listed.
NCT04094090 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04094090 about?
NCT04094090 is a clinical study titled "Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia". To evaluate the safety and effectiveness of the PXL Platinum 330 system for performing corneal cross-linking (CXL) for the treatment of ectatic disorders.
What is the current status of trial NCT04094090?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2019-10-19. Estimated completion is 2029-10-19.
What conditions does trial NCT04094090 study?
This clinical trial studies the following conditions: Keratoconus, Pellucid Marginal Corneal Degeneration, Corneal Ectasia.
What interventions are being tested in trial NCT04094090?
The interventions under investigation include: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04094090?
This trial is sponsored by Goodman Eye Center, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04094090 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratoconus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Effectiveness of the PXL-Platinum 330 System for Cornea Crosslinking in Eyes With Cornea Thinning
RECRUITING · Phase 2
-
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
RECRUITING · Phase 2
-
Comparison of Standard vs. Accelerated Corneal Crosslinking
RECRUITING · Phase 2
-
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
RECRUITING
-
OCT in Diagnosis of Irregular Corneas
RECRUITING
-
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.